Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Instagram Outage Disrupts Thousands of U.S. Users 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
SEATTLE, Nov. 23, 2017 -- According to Coherent Market Insights, the global pharmacogenomics market was valued at US$ 7,623.9 Million in 2016 and is projected to witness a CAGR of 7.6% over the forecast period (2017-2025). Many government agencies are actively supporting pharmacogenomics in drug development and surveillance, so that patients can benefit from advances in genomic science and technology.
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/pharmacogenomics-market-1053
Key Trends and Analysis of the Pharmacogenomics Market:
Among technology types, in 2016, the sequencing segment held the largest revenue share in the global pharmacogenomics market. This is majorly attributed to the increasing adoption of sequencing among researchers and clinicians, as it allows for accurate sequencing of complete human genomes. Among therapeutic applications, the oncology sub-segment holds a dominant position in the market. Precision oncology focuses on matching the most accurate and effective treatments that could benefit the patients based on the genetic profile of the cancer, as every cancer patient exhibits a different genetic profile to avoid the idea of one-size-fits-all in terms of cancer treatment. In 2014, National Cancer Institute (NCI) has also launched couple of precision medicine trials, which include Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials (ALCHEMIST), which are expected to boost the demand for precision medicines in the field of oncology.
Request Sample Copy of the Business Report
Key Market Takeaways:
- North America accounted for the largest revenue share in the global pharmacogenomics market. The prime driver for pharmacogenomics in North America is continuous advancement in pharmacogenomics research and genotyping technology to optimize medication therapy. In January 2015, in the U.S. President announced the Precision Medicine Initiative, which focuses on prevention and treatment approaches that account for inter-individual variability in drug response.
- Leading players in pharmacogenomics market are strategically involved in developing theranostics that can target one or two drugs most effective drugs for an individual. For instance, in 2001, Bayer and CuraGen Corporation stated two landmark biotechnology agreements. The first agreement was a comprehensive alliance to discover, develop, and jointly commercialize small molecule drugs to treat obesity and adult onset diabetes, whereas the second agreement was a broad collaboration to apply CuraGen’s functional genomic technologies.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
